Inhibition of aminoglycoside-induced nephrotoxicity in rats by polyanionic peptides.
In the present study, we compared poly-L-Asp with poly-L-Glu and poly-D-Glu in vitro and in vivo for their ability to inhibit the GM-induced nephrotoxicity. In vitro, all three polyanions (i) bound GM over a wide range of pH; (ii) displaced GM previously bound to negatively charged phospholipid bilayers at acid pH (i.e. under the conditions prevailing in lysosomes in vivo), and thereby (iii) decreased the inhibitory potency of GM towards lysosomal phospholipase A1. Thus, one was tempted to predict that all three polyanions would have the potential of protecting against AG-induced nephrotoxicity. However, when co-administered to rats with GM, poly-L-Asp and poly-D-Glu completely suppressed the development of lysosomal phospholipidosis, as assessed by biochemical criteria and increased drug accumulation, whereas poly-L-Glu did not offer such protection despite a relatively lower increase in drug accumulation levels. Histoautoradiography also confirmed that poly-L-Asp, but not poly-L-Glu, was a nephroprotectant against the tissue proliferative response induced by GM. Morphologically, poly-L-Asp almost completely and poly-D-Glu totally prevented the accumulation of myeloid bodies in lysosomes. In vitro incubation in the presence of purified lysosomal extracts revealed marked differences in the hydrolysis rate of these peptides (poly-D-Glu:poly-L-Asp:poly-L-Glu = 1:1.2:16.9). Assuming that all three polyanionic peptides are transported and accumulated in lysosomes to the same extent, these results not only suggest that their stability in lysosomes is an essential requisite for protection against lysosomal phospholipidosis, but also strengthen our hypothesis that the site of action of poly-L-Asp is inside the lysosomes but not at the level of the renal membranes. In addition, poly-D-Glu alone or combined with GM induced another type of morphological lesion, not related to AG-induced nephrotoxicity which, to our knowledge, has not yet been described.
Kishore
B K
BK
Laboratoire de Chimie Physiologique, Université Catholique de Louvain, Bruxelles, Belgium.
Lambricht
P
P
Ibrahim
S
S
Laurent
G
G
Tulkens
P M
PM
Maldague
P
P
D000818:Animals; D000838:Anions; D005260:Female; D005839:Gentamicins / Q000037:antagonists & inhibitors*; D006863:Hydrogen-Ion Concentration; D007674:Kidney Diseases / Q000139:chemically induced / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use*; D011099:Polyglutamic Acid / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D013237:Stereoisomerism
D000838:Anions; D005839:Gentamicins; D010455:Peptides; D011099:Polyglutamic Acid; C017645:polyaspartate